tDCS in Patients With Disorder of Consciousness Due to Severe Acquired Brain Injury

Cognitive Impairment Clinical Trial

Official title:

Observational Study on the Use of Transcranial Direct Stimulation in Patients With Disorder of Consciousness, Due to Severe Acquired Brain Injury, to Stimulate Recovery of Consciousness

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03367078
• Other study ID #: CE-17101
• Status: Terminated
• Start date: June 18, 2018
• Est. completion date: June 30, 2020

Study information

• Verified date: August 2020
• Source: Montecatone Rehabilitation Institute S.p.A.
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The present observational study is aimed at reporting the short-, mid- and long-term outcomes of patients with Disorder of Consciousness (DOC), in Vegetative State (VS) or Minimally Conscious State (MCS), due to a severe Acquired Brain Injury (sABI), after repeated treatments with anodal Transcranial Direct Current Stimulation (tDCS) on Left Dorsolateral Prefrontal Cortex (L-DLPFC), to stimulate recovery of consciousness. The results obtained will also be compared with those of a historical control cohort, before the introduction of tDCS, matched for demographic and clinical characteristics.

Description:

Patients surviving sABI resulting in a coma state, thanks to improvements in early intervention and intensive care technologies, in some cases begin to regain vigilance and consciousness within few weeks from the event. In other cases, however, while regaining vigilance, they may continue to present a DOC state. DOC patients, by definition, are unable to communicate and have severe motor, sensory and cognitive deficits. They can be in a Vegetative State (VS), characterized by wakefulness without consciousness, which can favorably evolve in a Minimally Conscious State (MCS).

Although there are currently no evidence-based guidelines on the treatment of DOC patients to facilitate their recovery of consciousness, several studies published in recent years have focused on various pharmacological and non-pharmacological interventions. Among these, there is a non-invasive stimulation technique, the Transcranial Direct Current Stimulation (tDCS), which has long been known for other indications. tDCS affects the neuronal membrane rest potential and is able to neuromodulate cortical excitability. Protocols in the literature describing the use of tDCS in DOC patients envisage anodal stimulation (active electrode) on the L-DLPFC area, with the reference electrode placed on a homologous controlateral area or on the controlateral shoulder. tDCS variants have also been described, both by type of current delivered and by active electrode's positioning, but they are still experimental.

The Montecatone Rehabilitation Institute (a 3rd level Italian hospital, specialized in intensive rehabilitation of sABI and spinal cord injured patients) has recently started adopting tDCS in clinical practice to stimulate recovery of consciousness of VS or MCS, post-sABI, patients. Since it was already known that a single tDCS applications is not sufficient to elicit detectable and durable responses, the Montecatone Institute's protocol envisages anode application on L-DLPFC area in a 20 minute daily session, possibly for 2 consecutive weeks (5 consecutive days per week). For a gradual and safe approach, 1 milliampere (mA) current intensity is applied during the first week, 2 mA during the second week.

The post-sABI DOC patients treated with tDCS at the Montecatone Institute, compared with the known literature, are more homogeneous with regard to the distance of time from the lesional event, moreover tDCS is administered at an earlier stage. The present observational, longitudinal study is aimed therefore at reporting the outcomes of such DOC patients treated with tDCS by evaluating them with functional and cognitive impairment scales, at short-term (at the conclusion of the first and second week of tDCS treatment), medium-term (3 months after the end of the treatment) and long-term (6 months after the end of the treatment). Electroencephalographic (EEG) pattern data will also be collected. The outcome data obtained will be compared with those of a historical control cohort too, matched for demographic and clinical characteristics. The present study aims at covering the lack in the literature of long-term follow-up data too.

It is expected that the results of the present study may be useful to provide concrete indications for planning further research studies aimed at evaluating the effectiveness of different techniques and/or protocols for application of tDCS in post-sABI DOC patients.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 1
• Est. completion date: June 30, 2020
• Est. primary completion date: June 30, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 16 Years and older

Eligibility

Inclusion Criteria:

• patients with Disorder of Consciousness, VS (= LCF 2) or MCS (= LCF 3), due to sABI;

• any etiology, with the exception of extensive haemorrhagic lesions;

• stable clinical conditions.

Exclusion Criteria:

• presence of implanted devices (e.g. pacemakers, intrathecal infusers);

• presence of metallic brain implants (clips) or intracranial implants;

• presence of extensive craniotomy involving the area of application of tDCS;

• history of epileptic seizure;

• mechanical ventilation in place;

• history of psychotic disorders;

• severe neurodegenerative pathology;

• pharmacotherapy with Na+ or Ca++ channel blockers (e.g. Carbamazepine) or with N-Methyl-D-aspartate (NMDA) receptor antagonists (e.g. Dextromethorphan);

• pregnancy in progress.

Related Conditions & MeSH terms

• Brain Injuries
• Cognitive Impairment
• Consciousness Disorders
• Minimally Conscious State
• Persistent Vegetative State
• Vegetative State
• Wounds and Injuries

Intervention

Device:
• Anodal tDCS
Anodal tDCS, on L-DLPFC area, is started 2 weeks after admission to the sABI Operative Unit with: one session per day (in the morning), possibly for 5 consecutive days per week (from Monday to Friday), for 2 consecutive weeks. Each tDCS session lasts 20 minutes. Current intensity is 1 mA during the first week, 2 mA in the second week

Other:
• Usual care
Usual care of DOC patients

Locations

Country	Name	City	State
Italy	Montecatone Rehabilitation Institute S.p.A.	Imola	BO

Sponsors (1)

Lead Sponsor	Collaborator
Montecatone Rehabilitation Institute S.p.A.

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in coma recovery in the tDCS cohort (short- and mid-term outcomes)	Assessment by Coma Recovery Scale-Revised (CRS-R) (on-line, where tDCS is administered)	Baseline (initial visit); tDCS session 5 (1 week); tDCS closing session 10 (2 weeks); follow-up 1 (1 week after tDCS closing session 10); follow-up 2 (3 months after tDCS closing session 10)
Primary	Change in cognitive functioning level in the tDCS cohort (short- and mid-term outcomes)	Assessment by Levels of Cognitive Functioning Scale (LCF) (off-line, i.e. where tDCS is administered, immediately after tDCS session)	Baseline (initial visit); tDCS session 5 (1 week); tDCS closing session 10 (2 weeks); follow-up 1 (1 week after tDCS closing session 10); follow-up 2 (3 months after tDCS closing session 10)
Secondary	Change in coma recovery in the tDCS cohort (long-term outcome)	Assessment by CRS-R scale	Baseline (initial visit); follow-up 3 (6 months after tDCS closing session 10)
Secondary	Change in cognitive functioning level in the tDCS cohort (long-term outcome)	Assessment by LCF scale	Baseline (initial visit); follow-up 3 (6 months after tDCS closing session 10)
Secondary	Change in disability level in the tDCS cohort (short-, mid- and long-term follow-up)	Assessment by Rappaport's Disability Rating Scale (DRS)	Baseline (initial visit); follow-up 1 (1 week after tDCS closing session 10); follow-up 2 (3 months after tDCS closing session 10); follow-up 3 (6 months after closing session 10)
Secondary	Change in electroencephalography pattern in the tDCS cohort	Assessment by electroencephalography (EEG) (off-line, i.e. where tDCS is administered, immediately after tDCS session)	Baseline (initial visit); tDCS tDCS closing session 10 (2 weeks)
Secondary	Change in coma recovery between the tDCS cohort and the Historical control cohort	Assessment by CRS-R scale	Baseline (initial visit); 3 months; 6 months
Secondary	Change in cognitive functioning level between the tDCS cohort and the Historical control cohort	Assessment by LCF scale	Baseline (initial visit); 3 months; 6 months
Secondary	Change in disability level between the tDCS cohort and the Historical control cohort	Assessment by DRS scale	Baseline (initial visit); 3 months; 6 months